Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study

J. J. F. Belch, B. Shaw, A. O'Dowd, A. Saniabadi, P. Leiberman, R. D. Sturrock, C. D. Forbes

    Research output: Contribution to journalArticle

    28 Citations (Scopus)

    Abstract

    Prostaglandin E1 (PGE1) and prostacyclin have been used in Raynaud's phenomenon (RP) but are unstable and require intravenous administration. An alternative approach is to stimulate the body's own PGE1 production via administration of the precursor essential fatty acid. We studied the effect of 12 capsules/day of evening primrose oil (EPO) on the manifestations of RP. 21 patients received a two week course of placebo, thereafter 11 received EPO for 8 weeks and 10 patients received placebo. As the weather worsened the placebo group experienced significantly more attacks than the EPO group. Visual analogue scales assessing the severity of attacks and coldness of hands improved in the EPO group. No changes were seen in either group in hand temperatures and cold challenge plethysmography. Blood tests showed some antiplatelet effects of the drug. In conclusion patients receiving EPO benefited symptomatically. This was not matched however by any change in objective assessment of blood flow, although changes in platelet behaviour and blood prostanoids were observed.
    Original languageEnglish
    Pages (from-to)490-494
    Number of pages5
    JournalThrombosis and Haemostasis
    Volume54
    Issue number2
    Publication statusPublished - 1985

    Fingerprint

    Raynaud Disease
    Double-Blind Method
    Alprostadil
    Placebos
    Hand
    Therapeutics
    Essential Fatty Acids
    Plethysmography
    Platelet Aggregation Inhibitors
    Weather
    Hematologic Tests
    Epoprostenol
    Visual Analog Scale
    Intravenous Administration
    Prostaglandins
    Capsules
    Blood Platelets
    Efamol

    Cite this

    Belch, J. J. F., Shaw, B., O'Dowd, A., Saniabadi, A., Leiberman, P., Sturrock, R. D., & Forbes, C. D. (1985). Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thrombosis and Haemostasis, 54(2), 490-494.
    Belch, J. J. F. ; Shaw, B. ; O'Dowd, A. ; Saniabadi, A. ; Leiberman, P. ; Sturrock, R. D. ; Forbes, C. D. / Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon : a double blind study. In: Thrombosis and Haemostasis. 1985 ; Vol. 54, No. 2. pp. 490-494.
    @article{18586907e7b64da8bf4dd4c9c6ded42d,
    title = "Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study",
    abstract = "Prostaglandin E1 (PGE1) and prostacyclin have been used in Raynaud's phenomenon (RP) but are unstable and require intravenous administration. An alternative approach is to stimulate the body's own PGE1 production via administration of the precursor essential fatty acid. We studied the effect of 12 capsules/day of evening primrose oil (EPO) on the manifestations of RP. 21 patients received a two week course of placebo, thereafter 11 received EPO for 8 weeks and 10 patients received placebo. As the weather worsened the placebo group experienced significantly more attacks than the EPO group. Visual analogue scales assessing the severity of attacks and coldness of hands improved in the EPO group. No changes were seen in either group in hand temperatures and cold challenge plethysmography. Blood tests showed some antiplatelet effects of the drug. In conclusion patients receiving EPO benefited symptomatically. This was not matched however by any change in objective assessment of blood flow, although changes in platelet behaviour and blood prostanoids were observed.",
    author = "Belch, {J. J. F.} and B. Shaw and A. O'Dowd and A. Saniabadi and P. Leiberman and Sturrock, {R. D.} and Forbes, {C. D.}",
    year = "1985",
    language = "English",
    volume = "54",
    pages = "490--494",
    journal = "Thrombosis and Haemostasis",
    issn = "0340-6245",
    publisher = "Schattauer Publishers",
    number = "2",

    }

    Belch, JJF, Shaw, B, O'Dowd, A, Saniabadi, A, Leiberman, P, Sturrock, RD & Forbes, CD 1985, 'Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study', Thrombosis and Haemostasis, vol. 54, no. 2, pp. 490-494.

    Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon : a double blind study. / Belch, J. J. F.; Shaw, B.; O'Dowd, A.; Saniabadi, A.; Leiberman, P.; Sturrock, R. D.; Forbes, C. D.

    In: Thrombosis and Haemostasis, Vol. 54, No. 2, 1985, p. 490-494.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon

    T2 - a double blind study

    AU - Belch, J. J. F.

    AU - Shaw, B.

    AU - O'Dowd, A.

    AU - Saniabadi, A.

    AU - Leiberman, P.

    AU - Sturrock, R. D.

    AU - Forbes, C. D.

    PY - 1985

    Y1 - 1985

    N2 - Prostaglandin E1 (PGE1) and prostacyclin have been used in Raynaud's phenomenon (RP) but are unstable and require intravenous administration. An alternative approach is to stimulate the body's own PGE1 production via administration of the precursor essential fatty acid. We studied the effect of 12 capsules/day of evening primrose oil (EPO) on the manifestations of RP. 21 patients received a two week course of placebo, thereafter 11 received EPO for 8 weeks and 10 patients received placebo. As the weather worsened the placebo group experienced significantly more attacks than the EPO group. Visual analogue scales assessing the severity of attacks and coldness of hands improved in the EPO group. No changes were seen in either group in hand temperatures and cold challenge plethysmography. Blood tests showed some antiplatelet effects of the drug. In conclusion patients receiving EPO benefited symptomatically. This was not matched however by any change in objective assessment of blood flow, although changes in platelet behaviour and blood prostanoids were observed.

    AB - Prostaglandin E1 (PGE1) and prostacyclin have been used in Raynaud's phenomenon (RP) but are unstable and require intravenous administration. An alternative approach is to stimulate the body's own PGE1 production via administration of the precursor essential fatty acid. We studied the effect of 12 capsules/day of evening primrose oil (EPO) on the manifestations of RP. 21 patients received a two week course of placebo, thereafter 11 received EPO for 8 weeks and 10 patients received placebo. As the weather worsened the placebo group experienced significantly more attacks than the EPO group. Visual analogue scales assessing the severity of attacks and coldness of hands improved in the EPO group. No changes were seen in either group in hand temperatures and cold challenge plethysmography. Blood tests showed some antiplatelet effects of the drug. In conclusion patients receiving EPO benefited symptomatically. This was not matched however by any change in objective assessment of blood flow, although changes in platelet behaviour and blood prostanoids were observed.

    M3 - Article

    C2 - 4082084

    VL - 54

    SP - 490

    EP - 494

    JO - Thrombosis and Haemostasis

    JF - Thrombosis and Haemostasis

    SN - 0340-6245

    IS - 2

    ER -

    Belch JJF, Shaw B, O'Dowd A, Saniabadi A, Leiberman P, Sturrock RD et al. Evening primrose oil (Efamol) in the treatment of Raynaud's phenomenon: a double blind study. Thrombosis and Haemostasis. 1985;54(2):490-494.